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ObesityBackground: Short-term survival after orthotopic liver transplantation (OLT) has improved over the past decades,
but long-term survival remains impaired. The effects of obesity on long-term survival after OLT are controversial.
Because pre-transplant body mass index (BMI) can be confounded by ascites, we hypothesized that post-
transplant BMI at 1 year could predict long-term survival.
Methods: A post-hoc analysis was performed of an observational cohort study consisting of adult recipients of a
first OLT between 1993 and 2010. Baseline BMI was measured at 1-year post-transplantation to represent a sta-
ble condition. Recipientswere stratified into normalweight (BMI b 25kg/m2), overweight (25 ≤ BMI ≤ 30kg/m2),
and obese (BMI N 30 kg/m2). Kaplan-Meier survival analyses were performedwith log-rank testing, followed by
multivariable Cox proportional hazards regression analysis.
Results: Out of 370 included recipients, 184 had normal weight, 136 were overweight, and 50 were obese at 1-
year post-transplantation. After median follow-up for 12.3 years, 107 recipients had died, of whom 46 (25%)
had normal weight, 39 (29%) were overweight, and 22 (44%) were obese (log-rank P= 0.020). Obese recipients
had a significantly increasedmortality risk compared to normalweight recipients (HR 2.00, 95% CI 1.08–3.68, P=
0.027). BMIwas inversely associatedwith 15 years patient survival (HR 1.08, 95% CI 1.03–1.14, P=0.001 per kg/
m2), independent of age, gender, musclemass, transplant characteristics, cardiovascular risk factors, kidney- and
liver function.
Conclusion:Obesity at 1-year post-transplantation conveys a 2-fold increasedmortality risk, whichmay offer po-
tential for interventional strategies (i.e. dietary advice, lifestyle modification, or bariatric surgery) to improve
long-term survival after OLT.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Orthotopic liver transplantation (OLT) is the life-saving treatment
for patients suffering from end-stage liver disease [1]. Although short-
term survival has improved over the past decades, long-term survival
remains impaired. Overall 1- and 5-year survival rates after OLT aree Transaminase; AST, Aspartate
Area; CER, Creatinine Excretion
aboration; DBP, Diastolic Blood
n Rate; γ-GT, Gamma-
U, Intensive Care Unit; MELD,
teatohepatitis; OLT, Orthotopic
; SBP, Systolic Blood Pressure.
y and Liver Transplantation,
ngen, P.O. Box 30.001, 9700 RB
).
. This is an open access article under90% and 70% respectively [2,3], whereas 20-year survival rate is approx-
imately 50% [4]. This emphasizes the importance to identify risk factors
for long-term outcomes in OLT recipients. Several risk factors have al-
ready been shown to impair long-term outcomes after OLT, such as pri-
mary liver disease [5,6], older recipient and donor age [5–7], as well as
the livelong dependency on chronic immunosuppression therapy [8],
which predisposes to the development of de novo malignancies [9],
renal dysfunction [10,11], hypertension [2,12], new onset of diabetes
mellitus [13,14], and hyperlipidaemia [12]. However, the effects of
overweight and obesity on long-term survival after OLT remain
contradictory [15].
Overweight and obesity are characterized by an abnormal or exces-
sive fat accumulation that may impair health and is measured by the
body mass index (BMI) [16]. In the general population, overweight
and obesity are a major problem. Overall, in 2016, approximately 39%
of the world's adult population was overweight, and 13% were obese
[16]. Furthermore, the worldwide prevalence of obesity nearly tripledthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Baseline characteristics of the overall OLT recipient population and according to BMI-stratified groups.
Overall OLT recipients (n= 370) Normal weight (n= 184) Overweight (n= 136) Obese (n= 50) P-value
Men (%) 214 (57.8) 105 (57.1) 86 (63.2) 23 (46.0) 0.103
Demographics
Age, y 48.5 ± 12.5 45.5 ± 13.0 51.4 ± 11.3 51.4 ± 10.9 b0.001
Current smoker, n (%) 50 (17.5) 27 (18.5) 18 (17.3) 5 (14.3) 0.839
Body composition
Height, m 1.73 ± 0.10 1.75 ± 0.11 1.73 ± 0.09 1.69 ± 0.11 0.001
Weight, kg 77.0 ± 14.7 68.5 ± 10.0 81.2 ± 9.0 97.1 ± 17.3 b0.001
BMI, kg/m2 25.7 ± 4.5 22.4 ± 2.0 27.0 ± 1.4 34.0 ± 3.7 b0.001
BSA, m2 1.90 ± 0.21 1.82 ± 0.19 1.96 ± 0.16 2.06 ± 0.23 b0.001
Urinary CER (mmol/24 h) (m) 13.1 (10.7–15.4) 12.7 (10.5–14.8) 13.5 (11.3–16.3) 13.0 (10.7–17.0) 0.106
Urinary CER (mmol/24 h) (f) 9.2 (7.7–11.0) 8.8 (7.5–10.5) 9.6 (7.9–11.5) 10.1 (7.6–11.8) 0.274
Medical history
Cardiovascular disease, n (%) 18 (4.9) 6 (3.3) 9 (6.6) 3 (6.0) 0.356
Hypertension, n (%) 225 (61.0) 90 (49.2) 93 (68.4) 42 (84.0) b0.001
Circulation
Heart rate, bpm 73.3 ± 9.8 73.1 ± 9.4 73.7 ± 10.3 72.9 ± 10.3 0.902
SBP, mmHg 133.0 ± 15.3 130.2 ± 14.7 134.9 ± 15.2 138.3 ± 16.0 0.001
DBP, mmHg 81.9 ± 9.1 80.4 ± 9.3 82.9 ± 8.7 84.5 ± 8.8 0.004
Renal function
eGFR, ml/min per 1.73 m2 69.7 ± 21.7 73.5 ± 24.0 65.9 ± 18.5 65.6 ± 18.2 0.003
Serum creatinine, μmol/L 104.6 ± 31.1 103.1 ± 36.3 107.0 ± 24.1 103.6 ± 27.0 0.520
Proteinuria, n (%) 39 (10.7) 17 (9.3) 14 (10.4) 8 (16.3) 0.368
Laboratory parameters
Triglycerides, mmol/L 1.5 (1.2–2.2) 1.5 (1.0–1.9) 1.6 (1.2–2.3) 1.9 (1.3–2.5) 0.002
Total cholesterol, mmol/L 5.0 ± 1.4 4.9 ± 1.5 5.2 ± 1.3 5.1 ± 1.3 0.337
Glucose, mmol/L 5.7 (4.7–6.6) 5.4 (4.6–6.3) 5.8 (4.9–7.2) 6.3 (5.3–6.9) 0.001
Haemoglobin, mmol/L 8.0 ± 1.2 7.9 ± 1.3 8.1 ± 1.0 7.8 ± 0.9 0.084
Albumin, g/L 41.8 ± 4.5 41.6 ± 5.0 42.2 ± 4.0 41.1 ± 4.2 0.256
AST, U/L 26.5 (21.0–39.2) 26.3 (21.0–30.0) 26.8 (21.7–38.0) 26.6 (20.5–56.1) 0.926
ALT, U/L 28.2(19.0–49.1) 27.0 (18.1–49.4) 28.7 (20.8–47.5) 28.5 (20.8–58.0) 0.508
γ-GT, U/L 43.0 (22.0–126.5) 42.0 (20.3–122.7) 42.8 (22.5–133.2) 50.5 (24.5–144.5) 0.800
ALP, U/L 86.8 (64.9–126.1) 87.0 (62.5–137.5) 84.5 (65.0–113.5) 92.2 (66.7–126.3) 0.577
Bilirubin total, μmol/L 16.3 (11.5–23.4) 16.7 (11.5–26.9) 16.0 (11.3–21.0) 16.8 (11.8–23.2) 0.531
Bilirubin direct, μmol/L 5.8 (3.0–9.6) 6.0 (3.2–11.0) 5.0 (2.7–8.0) 5.5 (3.0–10.6) 0.075
Primary liver disease b0.001
Acute liver failure, n (%) 21 (5.7) 13 (7.1) 6 (4.4) 2 (4.0)
Viral hepatitis, n (%) 52 (14.1) 19 (10.3) 25 (18.4) 8 (16.0)
Autoimmune hepatitis, n (%) 27 (7.3) 17 (9.2) 9 (6.6) 1 (2.0)
Primary biliary cholangitis, n (%) 32 (8.6) 12 (6.5) 13 (9.6) 7 (14.0)
Primary sclerosing cholangitis, n (%) 73 (19.7) 49 (26.6) 20 (14.7) 4 (8.0)
Cryptogenic + NASH, n (%) 46 (12.4) 15 (8.2) 17 (12.5) 14 (28.0)
Alcohol cirrhosis, n (%) 47 (12.7) 13 (7.1) 24 (17.6) 10 (20.0)
Storage disorders, n (%) 21 (5.7) 9 (4.9) 9 (6.6) 3 (6.0)
Other, n (%) 51 (13.8) 37 (20.1) 13 (9.6) 1 (2.0)
Transplant characteristics
Cold ischemia time, hours 8.1 (6.9–10.0) 8.1 (6.7–10.2) 8.2 (7.1–10.0) 7.9 (6.1–10.5) 0.473
Warm ischemia time, minutes 48.0 (41.5–57.0) 48.0 (41.8–57.0) 48.0 (42.0–57.0) 48.0 (41.0–57.0) 0.981
Age donor, years 43.7 ± 14.6 43.3 ± 14.8 43.5 ± 14.1 45.8 ± 14.9 0.544
Heart-beating donor, n (%) 331 (89.5) 166 (90.2) 122 (89.7) 43 (86.0) 0.685
Transplant era, n (%) 0.263
1993–1998 112 (30.3) 55 (29.9) 44 (32.4) 13 (26.0)
1999–2004 131 (35.4) 74 (40.2) 41 (30.1) 16 (32.0)
2005–2010 127 (34.3) 55 (29.9) 51 (37.5) 21 (42.0)
Transplant complications
Relaparotomy, n (%) 54 (14.6) 28 (15.2) 19 (14.0) 7 (14.0) 0.879
ICU stay, days 3.0 (1.0–7.0) 3.0 (1.0–7.5) 3.0 (2.0–7.0) 4.0 (2.0–8.0) 0.501
Pre-transplant MELD score 14.2 (10.0–20.8) 13.7 (8.7–20.0) 14.5 (10.0–21.4) 14.9 (11.5–23.2) 0.519
Pre-transplant ascites 0.049
None 173 (53.1) 91 (55.2) 60 (51.7) 22 (48.9)
Mild 79 (24.2) 44 (26.7) 21 (18.1) 14 (31.1)
Moderate 47 (14.4) 23 (13.9) 18 (15.5) 6 (13.3)
Severe 27 (8.3) 7 (4.2) 17 (14.7) 3 (6.7)
Medication
Calcineurin inhibitor, n (%)
Cyclosporine 157 (42.4) 74 (40.2) 61 (44.9) 22 (44.0) 0.689
Tacrolimus 194 (52.4) 98 (53.3) 68 (50.0) 28 (56.0) 0.730
Proliferation inhibitor, n (%)
Azathioprine 165 (44.6) 85 (46.2) 58 (42.6) 22 (44.0) 0.816
Mycophenolate mofetil 58 (15.7) 26 (14.1) 20 (14.7) 12 (24.0) 0.218
Prednisolone, n (%) 317 (85.7) 162 (88.0) 114 (83.8) 41 (82.0) 0.412
Prednisolone dose, mg/day 10.0 (7.5–10.0) 10.0 (7.5–10.0) 10.0 (7.5–10.0) 10.0 (7.5–10.0) 0.273
Cumulative prednisolone dose, g 3.7 (1.8–4.6) 3.7 (2,0–5.5) 3.6 (1.1–4.0) 3.6 (0.5–4.2) 0.035
Antidiabetics, n (%) 75 (20.3) 25 (13.6) 31 (22.8) 19 (38.0) b0.001
Antihypertensives, n (%) 183 (49.5) 67 (36.4) 80 (58.8) 36 (72.0) b0.001
Statins, n (%) 32 (8.6) 5 (2.7) 18 (13.2) 9 (18.0) b0.001
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Fig. 1. Actuarial survival for all-cause mortality according to BMI-stratified groups.
3J. van Son et al. / Metabolism Clinical and Experimental 106 (2020) 154204between 1975 and 2016. In the general population, high BMI is a risk
factor for cardiovascular diseases, diabetes, musculoskeletal disorders,
and cancer, resulting in increased morbidity and mortality [16].
Pre-transplantation overweight and obesity are very common inOLT
recipients. The prevalence of overweight and obesity has been reported
to be 41% and 28%, respectively [17]. Additionally, alcoholic liver dis-
ease, hepatocellular carcinoma, genetic factors, and male gender are
risk factors for new-onset obesity after liver transplantation [18]. His-
tory of smoking and higher age are also associatedwith an increased in-
cidence of obesity after OLT [19]. Because OLT recipients are prone to
develop overweight or obesity post-transplantation [20], it is important
to investigate the effects of overweight and obesity on long-term sur-
vival after OLT.
As pre-transplant bodyweight can be confounded by ascites, it is es-
timated that 11–20% of patients with large volume ascites are
misclassified as being overweight or obese [21,22]. Furthermore, OLT
recipients gain weight after transplantation, mainly during the first
year after OLT [23]. Therefore, post-transplant body weight is likely to
be more representative to calculate true BMI. In this study, we hypoth-
esized that post-transplant BMI at 1 year after OLT is associated with
long-term survival.2. Methods
2.1. Study design and population
A post-hoc analysis of an observational cohort study (www.
trialregister.nl – Trial NL6334) of adult (age ≥18 years) patients, who
underwent a first OLT between 1993 and 2010,was performed. Baseline
was set at 1 year post-transplantation to represent a stable condition
and because most weight gain occurs within the first year afterNote to Table 1:
Data are represented as mean ± SD, median (interquartile range) or n (%). Differences were te
variables. BMI, bodymass index; BSA, body surface area; CER; creatinine excretion rate; SBP, sy
rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GT, gamma-glutamylt
care unit; MELD, model for end-stage liver disease.transplantation [23]. OLT recipients with missing baseline data on
BMI, age, gender, or urinary creatinine excretion rate (CER) were ex-
cluded. Furthermore, those OLT recipients who died within 1 year
after transplantation and those who were lost to follow-up were ex-
cluded. OLT recipients were stratified into normal weight (BMI
b 25 kg/m2), overweight (25 ≤ BMI ≤ 30 kg/m2), and obese (BMI
N 30 kg/m2). This studywas approved by theMedical Ethical Committee
of our institute (METc 2014/77) and adhered to the Declaration of Hel-
sinki and the Declaration of Istanbul.2.2. Data collection
Gender, age, current smoking status, height, weight, primary liver
disease, complications, and medication use were derived from patient
records. Transplant characteristicswere derived from the recipient's op-
erative report. Donor characteristics were retrieved from the
Eurotransplant database.
BMI was obtained by dividing a person's weight by the square of the
person's height (kg/m2). Body surface area (BSA) was calculated using
the DuBois formula [24]. Cardiovascular disease history was defined as
a previous myocardial infarction, cerebrovascular accident, and/or pe-
ripheral arterial disease. Hypertension was defined as a blood pressure
of N140/90 mmHg and/or the use of antihypertensive medication.
Cumulative prednisolone dose was calculated as the daily predniso-
lone dose at baseline, multiplied by the number of days since transplan-
tation, adding the dosage of prednisolone or methylprednisolone given
for treatment of rejection. Methylprednisolone dosage was converted
into prednisolone equivalents by multiplying methylprednisolone dos-
age by a factor of 1.25 [25]. To account for differences in immunosup-
pressive regimes, transplantation dates were stratified into 3 era's.
During the first era (1993–1998), a combination of prednisolonested by ANOVA or Kruskal-Wallis for continuous variables and with χ2-test for categorical
stolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration
ransferase; ALP, alkaline phosphatase; NASH, non-alcoholic steatohepatitis; ICU, intensive
Fig. 2. Proportion of deceased OLT recipients according to BMI groups. Differences between groups assessed with χ2-test; ns, not significant; ⁎P b 0.05; ⁎⁎P b 0.01.
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resulting in trough blood levels of 100 μg/L) was given. During the sec-
ond era (1999–2004), a combination of prednisolone and tacrolimus
(dosage resulting in trough blood levels between 5 and 7 μg/L) could
be given, as well as the combination of prednisolone, azathioprine,
and cyclosporin A. Finally, during the third era (2005–2010), a combi-
nation of prednisolone, mycophenolate mofetil, and tacrolimus was
given.
All serum and urine laboratory parameters were derived from our
center's electronic laboratory system, using themedian values between
9- and 15-months post-transplantation to minimize collection and
measurement errors. OLT recipients were instructed to collect their
urine according to a standardized protocol. For 24 subsequent hours, re-
cipients collected urine, excluding themorning urine of the first day and
including their morning urine of the second day. Kidney function was
determined using the estimated glomerular filtration rate (eGFR),
which was calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) formula [26]. Proteinuria was defined as uri-
nary protein excretion of N0.5 g/day. Muscle mass was estimated
using urinary CER, obtained from 24 h urine samples [25].
Causes of death were derived from patient records or requested
from general practitioners, and categorized into cardiovascular, infec-
tious, malignant, and miscellaneous.Table 2
Causes of death of the overall OLT recipient population and according to BMI-stratified groups
Overall OLT recipients (n= 107) Normal weight (n
Cardiovascular 24 (22.4) 14 (30.4)
Infectious 28 (26.2) 11 (23.9)
Malignant 33 (30.8) 11 (23.9)
Miscellaneous 22 (20.6) 10 (21.7)
Chi-square = 9.80; P= 0.133.2.3. Outcome measures and follow-up
The primary outcome of this study was 15 years all-cause mortality.
The secondary outcome was cause-specific mortality divided into four
categories: cardiovascular, infectious, malignancy, and miscellaneous.
Follow-upwas recorded up to 15 years after baseline, or until December
31, 2018.
2.4. Statistical analyses
Continuous variables are presented as mean ± standard deviation
(SD) if normally distributed and as median (interquartile range [IQR])
if skewed. Categorical variables are presented as number (percentage).
Differences across BMI stratified groups were compared using the one-
way analysis of variance (ANOVA) for normally distributed variables,
the Kruskal-Wallis test for skewed distributed variables, and chi-
square test for categorical variables.
Kaplan-Meier analysis with the log-rank testwas used for initial sur-
vival analysis. Subsequently, Schoenfeld residuals were investigated to
test the proportionality of hazards. Cox proportional hazards regression
analyses were performed for BMI as categorical variable as well as con-
tinuous variable. Data were presented as hazard ratios (HR) and 95%
confidence intervals (CI). Potential interactions of BMIwith age, gender,.
= 46) Overweight (n= 39) Obese (n= 22) P value
8 (20.5) 2 (9.1) 0.184
12 (30.8) 5 (22.7) 0.723
15 (38.5) 7 (31.8) 0.337
4 (10.3) 8 (36.4) 0.046
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constructed to adjust for potential confounders.
In model 1, we performed a crude Cox proportional hazards regres-
sion analysis. Subsequently, multivariable Cox proportional hazards re-
gression analyses were performed. In model 2, we adjusted for body
composition, using age, gender, and muscle mass as measured urinary
CER. Inmodel 3,we cumulatively adjusted for transplant related factors,
including primary liver disease and transplantation era. In model 4 we
cumulatively adjusted for independent cardiovascular risk factors, in-
cluding cardiovascular disease history and smoking status. In model 5,
we cumulatively adjusted for kidney function, using eGFR and the pres-
ence of proteinuria. Finally, in model 6, cumulative adjustments were
made for liver function, using liver enzymes (AST, ALT, gamma-GT,
ALP), direct bilirubin, and serum albumin. No adjustments were made
for the use of calcineurin inhibitors and prednisolone, since transplanta-
tion eras are based on medication regimes. However, variations in the
standard regimens were present and were related to side effects or
treatment of allograft rejection [27,28]. Therefore, sensitivity analyses
were performed, replacing transplantation era by the use of calcineurin
inhibitors and/or prednisolone and/or cumulative prednisolone dose.
Additionally, univariable and multivariable Cox proportional haz-
ards regression analyses were performed for all baseline variables, ex-
cluding variables with N10% missing values. Multivariable analysis was
performed including all variables with P b 0.1 in the univariate analysis
and gender. When variables were represented by other variables (e.g.
serum creatinine and eGFR), the most significant variable was included
in the multivariable analysis.
Cause-specific mortality was assessed using cox proportional haz-
ards analysis and subsequently, predictors of cardiovascular mortality
were assessed, using competing-risks regression models according to
Fine and Gray [29].
To assess the effect of change in BMI in the first-year post-
transplantation compared to pre-transplantation on all-causemortality,
additional analyses were performed using the models described above.
Change in BMIwas calculated as BMI 1-year post-transplantationminus
BMI pre-transplantation. For BMI pre-transplantation the last docu-
mented BMI before transplantation was used. Because pre-transplant
BMI is affected by ascites, we additionally performed analyses
correcting for pre-transplant ascites in model 2, and excluding patients
with pre-transplant ascites.
To visualize the relationship between BMI and all-cause mortality, a
multivariable adjusted, restricted cubic splinewith 3 knots positioned atTable 3
Association of BMI with all-cause mortality.
Normal Overweight
Ref. HR
(95% CI)
P value
No. of events (%) ➔ 46 (25.0) 39 (28.7)
Model 1 1.00 1.19
(0.78–1.83)
0.421
Model 2 1.00 0.99
(0.64–1.54)
0.974
Model 3 1.00 1.02
(0.64–1.62)
0.934
Model 4 1.00 1.05
(0.66–1.67)
0.829
Model 5 1.00 1.05
(0.65–1.68)
0.855
Model 6 1.00 1.09
(0.67–1.77)
0.730
Model 1: crude.
Model 2: adjustment for age, gender and urinary CER.
Model 3:model 2 + adjustment for primary liver disease and transplantation era.
Model 4:model 3 + adjustment for cardiovascular disease history and smoking status.
Model 5:model 4 + adjustment for eGFR and proteinuria.
Model 6:model 5 + adjustment for liver enzymes (AST, ALT, γ -GT, and ALP), direct bilirubin,the 10th, 50th, and 90th was made, based on model 6. Median BMI was
used as reference.
P values are two-tailed and for all analyses a P value of b0.05 was
considered to be statistically significant. Statistical analyses were per-
formed, using IBM Statistics SPSS version 23.0 (IBM Inc. Chicago, IL),
Stata/SE 14.2 (StataCorp LLC. College Station, TX), GraphPad Prism
7.02 (GraphPad Software, Inc. San Diego, CA), and R version 3.5.1 (R
Foundation, Vienna, Austria).
3. Results
Between 1993 and 2010, a total of 393 adult patients underwent
OLT. Nine OLT recipients died within the first year after transplantation
and were excluded, as well as 13 OLT recipients with missing baseline
data on BMI. Additionally, one recipient was lost to follow-up, resulting
in 370 OLT recipients eligible for analysis. The majority of 184 (49.7%)
OLT recipients had a normal weight, whereas 136 (36.8%) were over-
weight, and 50 (13.5%) were obese.
Baseline characteristics according to BMI categories are described in
Table 1. Of all OLT recipients, 214 (57.8%)weremale, with no significant
differences between groups. Mean age was 48.3 ± 12.5 years, with
normal-weight OLT recipients being significantly younger than those
with a higher BMI classification. Mean BMI was 25.7 ± 4.5 kg/m2.
Concerning body composition, weight, BMI, and BSA, were significantly
higher, whereas height was significantly lower in the obese group com-
pared to lower BMI groups. However, no significant differences were
found in urinary CER between groups. Hypertension was present in
225 (60.8%) OLT recipients and significantly higher in the obese group
compared to lower BMI groups. Mean eGFR was 69.7 ± 21.6 ml/min/
1.73m2, with normal-weight OLT recipients having a significantly
higher eGFR than overweight or obese OLT recipients. Serum triglycer-
ides and glucosewere significantly higher in the obese group compared
to lower BMI groups, as well as the use of antidiabetics, antihyperten-
sives, and statins.
Significant differences were seen between BMI groups and primary
liver disease (P b 0.001). Primary sclerosing cholangitis (PSC) was
most common in normal weight OLT recipients, viral hepatitis and alco-
hol cirrhosis were most common in overweight OLT recipients, and
cryptogenic cirrhosis/non-alcoholic steatohepatitis (NASH) and alcohol
cirrhosis were most common in obese OLT recipients.
Kaplan-Meier survival curves are depicted in Fig. 1. During amedian
follow-up of 12.3 years (IQR 8.4–15.0 years), 107 (28.9%) OLT recipientsObese BMI continuous
HR
(95% CI)
P value HR
(95% CI)
P value
22 (44.0) 107 (28.9)
2.04
(1.23–3.39)
0.006 1.08
(1.04–1.12)
b0.001
1.80
(1.07–3.03)
0.026 1.07
(1.02–1.12)
0.002
1.88
(1.07–3.32)
0.029 1.08
(1.03–1.13)
0.002
2.00
(1.12–3.55)
0.019 1.08
(1.03–1.13)
0.002
2.00
(1.10–3.63)
0.023 1.08
(1.03–1.13)
0.003
2.00
(1.08–3.68)
0.027 1.08
(1.03–1.14)
0.001
and albumin.
Table 4
Predictors for 15 years all-cause mortality.
Univariable analysis Multivariable analysis
BMI, per kg/m2 1.08 (1.04–1.12) b0.001 1.08 (1.03–1.14) 0.002
Gender, male/female 1.19 (0.80–1.75) 0.389 2.10 (1.20–3.66) 0.009
Age, per year 1.04 (1.03–1.06) b0.001 1.03 (1.01–1.06) 0.009
Current smoking status, yes/no
No 1.00 (Ref.) 1.00 (Ref.)
Yes 1.74 (1.07–2.82) 0.025 1.51 (0.88–2.58) 0.132
Unknown 0.93 (0.55–1.55) 0.769 0.83 (0.46–1.52) 0.556
Height, per m 0.70 (0.11–4.33) 0.700
Weight, per kg 1.02 (1.01–1.03) 0.004
BSA, per m2 2.36 (0.95–5.90) 0.066
Urinary CER, per mmol/24 h 0.62 (0.42–0.91) 0.015 0.57 (0.33–0.97) 0.040
Cardiovascular disease, yes/no 2.00 (1.02–3.96) 0.046 0.86 (0.40–1.82) 0.687
Hypertension, yes/no 1.29 (0.87–1.92) 0.210
Heart rate, per bpm 0.99 (0.97–1.02) 0.580
SBP, per mmHg 1.00 (0.99–1.01) 0.731
DBP, per mmHg 0.99 (0.97–1.01) 0.427
eGFR, per 10 ml/min per 1.73 m2 0.90 (0.81–0.99) 0.024 0.98 (0.86–1.13) 0.798
Serum creatinine, per 10 μmol/L 1.06 (1.00–1.12) 0.035
Proteinuria, yes/no 1.34 (0.76–2.35) 0.309
Total cholesterol, per mmol/L 1.05 (0.92–1.21) 0.475
Glucose, per mmol/L 1.09 (1.01–1.18) 0.030 1.02 (0.93–1.12) 0.683
Haemoglobin, per mmol/L 0.97 (0.82–1.15) 0.743
Albumin, per g/L 0.92 (0.89–0.96) b0.001 0.92 (0.88–0.97) 0.001
AST, per U/L 1.00 (1.00–1.00) 0.879
ALT, per U/L 1.00 (1.00–1.00) 0.800
γ-GT, per U/L 1.00 (1.00–1.00) 0.371
ALP, per 10 U/L 1.01 (1.00–1.02) 0.050 0.99 (0.98–1.01) 0.501
Bilirubin total, per μmol/L 1.00 (0.99–1.01) 0.958
Bilirubin direct, per μmol/L 1.00 (1.00–1.01) 0.254
Primary liver disease, yes/no
Acute liver failure 0.45 (0.10–1.98) 0.293 0.50 (0.11–2.26) 0.365
Viral hepatitis 1.67 (0.83–3.38) 0.153 0.72 (0.32–1.62) 0.421
Autoimmune hepatitis 1.97 (0.89–4.39) 0.096 2.39 (1.03–5.50) 0.041
Primary biliary cholangitis 1.23 (0.52–2.90) 0.636 0.88 (0.34–2.29) 0.792
Primary sclerosing cholangitis 1.00 (Ref.) 1.00 (Ref.)
Cryptogenic + NASH 2.59 (1.32–5.11) 0.006 1.09 (0.48–2.48) 0.840
Alcohol cirrhosis 2.40 (1.22–4.74) 0.011 0.87 (0.40–1.89) 0.721
Storage disorders 0.68 (0.20–2.35) 0.545 0.42 (0.11–1.57) 0.196
Other 1.56 (0.76–3.19) 0.223 1.56 (0.73–3.34) 0.256
Age donor, per 10 years 1.21 (1.05–1.39) 0.008 1.06 (0.90–1.26) 0.458
Heart-beating donor, yes/no 0.56 (0.32–0.99) 0.044 0.90 (0.45–1.83) 0.780
Transplant era, yes/no
1993–1998 1.00 (Ref.) 1.00 (Ref.)
1999–2004 1.47 (0.92–2.34) 0.103 0.97 (0.55–1.71) 0.903
2005–2010 1.56 (0.93–2.61) 0.094 0.98 (0.45–2.14) 0.966
Cyclosporine, yes/no 0.68 (0.46–1.01) 0.055 0.68 (0.86–1.03) 0.208
Tacrolimus, yes/no 1.11 (0.76–1.62) 0.599
Azathioprine, yes/no 0.90 (0.61–1.31) 0.576
Mycophenolate mofetil, yes/no 1.21 (0.71–2.06) 0.489
Prednisolone, yes/no 0.82 (0.47–1.42) 0.481
Prednisolone dose, per mg/day 0.99 (0.94–1.04) 0.661
Cumulative prednisolone dose, per g 0.91 (0.85–0.99) 0.020 0.94 (0.86–1.03) 0.208
Antidiabetics, yes/no 1.70 (1.10–2.61) 0.016 1.12 (0.65–1.95) 0.680
Antihypertensives, yes/no 1.21 (0.83–1.78) 0.316
Statins, yes/no 2.01 (1.12–3.61) 0.020 1.05 (0.51–2.15) 0.899
Univariable andmultivariable Cox proportional hazards regression analyseswere performed for all variableswith b10%missing values. Multivariable analysiswas performed including all
variables with P b 0.1 in the univariate analysis and gender. When variables were represented by other variables (e.g. serum creatinine and eGFR) the most significant variable was in-
cluded in the multivariable analysis.
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died, 39 (28.7%) OLT recipients in the overweight group died and 22
(44.0%) OLT recipients in the obese group died (Fig. 1, log-rank test: P
= 0.020; Fig. 2). Twenty-four (22.4%) OLT recipients died as a result of
cardiovascular causes, 28 (26.2%) OLT recipients died due to infectious
causes, and for 33 (30.8%) OLT recipients their cause of deathwasmalig-
nant disease. Additionally, 22 (20.6%) OLT recipients died as a result of
other causes, including recurring liver cirrhosis (n = 8), amyloidosis
(n = 6), suicide or euthanasia (n = 3), neurologic causes (n = 2),
graft failure (n= 1), lung emphysema (n = 1), and kidney failure due
to azathioprine use (n = 1). No significant differences were found in
causes of death between BMI groups (Table 2).Results of Cox proportional hazards regression analyses are de-
scribed in Tables 3 and 4. We found no evidence for interactions of
BMI with age, gender, or urinary CER (all P ≥ 0.05). Analyses according
to BMI categories showed that obese OLT recipients had a significantly
2-fold higher risk of all-cause mortality (Table 3, model 1: HR = 2.04,
95% CI: 1.23–3.39, P = 0.006), when compared to normal weight OLT
recipients. Multivariable adjustments for age, gender, urinary CER, pri-
mary liver disease, transplantation era, cardiovascular risk factors, kid-
ney function, and liver function (Table 3, models 2–6) did not
materially alter these results (Table 3, model 6: HR = 2.00, 95% CI:
1.08–3.68, P = 0.027). As a continuous variable, BMI was associated
with higher all-cause mortality (Table 3, model 1 and Table 4, HR =
Fig. 3. Restricted cubic splines visualizing adjusted hazards ratio for BMI on all-cause
mortality. Adjustments were made according to model 6. The black line represents the
association of BMI on all-cause mortality. The gray area represents the 95% confidence
interval.
Table 6
Change in BMI categories during the first year after OLT.
7J. van Son et al. / Metabolism Clinical and Experimental 106 (2020) 1542041.08, 95% CI: 1.04–1.12, P b 0.001). Results remained similar indepen-
dent of multivariable adjustments (Table 3, model 6: HR = 1.08, 95%
CI: 1.03–1.14, P= 0.001; and Table 4, HR = 1.08, 95% CI: 1.03–1.14, P
= 0.002). This association is graphically depicted in Fig. 3.Table 5
Association of BMI with cause-specific mortality.
BMI continuous
HR
(95% CI)
P value
No. of events (%) cardiovascular 24 (6.5)
Model 1 0.91 (0.81–1.01) 0.084
Model 2 0.94 (0.84–1.06) 0.327
Model 3 0.95 (0.84–1.08) 0.428
Model 4 0.99 (0.87–1.14) 0.933
Model 5 1.03 (0.90–1.18) 0.670
Model 6 1.04 (0.90–1.21) 0.559
No. of events (%) infectious 28 (7.6)
Model 1 1.05 (0.97–1.14) 0.202
Model 2 1.09 (1.00–1.18) 0.043
Model 3 1.11 (1.01–1.22) 0.039
Model 4 1.09 (0.98–1.21) 0.123
Model 5 1.11 (1.00–1.23) 0.050
Model 6 1.12 (1.00–1.25) 0.046
No. of events (%) malignant 33 (8.9)
Model 1 1.04 (0.96–1.12) 0.347
Model 2 1.03 (0.95–1.12) 0.523
Model 3 1.04 (0.94–1.14) 0.488
Model 4 1.06 (0.95–1.18) 0.275
Model 5 1.04 (0.93–1.17) 0.491
Model 6 1.07 (0.95–1.20) 0.243
No. of events (%) miscellaneous 22 (5.9)
Model 1 1.06 (0.97–1.16) 0.176
Model 2 1.06 (0.97–1.17) 0.198
Model 3 1.09 (0.99–1.21) 0.072
Model 4 1.07 (0.96–1.19) 0.247
Model 5 a)
Model 6 a)
Model 1: crude.
Model 2: adjustment for age, gender and urinary CER.
Model 3:model 2 + adjustment for primary liver disease and transplantation era.
Model 4:model 3 + adjustment for cardiovascular disease history and smoking status.
Model 5:model 4 + adjustment for eGFR and proteinuria.
Model 6:model 5 + adjustment for liver enzymes (AST, ALT, γ-GT, and ALP), direct bili-
rubin, and albumin.
a) Not enough variables for reliable presentation.Sensitivity analyses replacing transplantation era in model 3 by the
use of calcineurin inhibitors and/or the use of prednisolone and/or cu-
mulative prednisolone dose did not materially change the results for
continuous and stratified analyses (Supplementary Table S1).
Additional Cox regression analyses were performed to investigate the
association of BMI with cause-specific mortality (Table 5). A significant
association of BMI with infectious mortality was found (Table 5, model
6: HR=1.12, 95% CI: 1.00–1.25, P=0.046).We found no statistically sig-
nificant associations for BMIwith cardiovascular,malignant, andmiscella-
neous mortality. Competing-risks regression models on cardiovascular
mortality are described in Supplementary Table S2. Cardiovascular dis-
ease history (SHR = 4.33, 95% CI: 1.46–12.82, P = 0.008), current
smoking status (SHR= 4.05, 95% CI: 1.69–9.71, P=0.002), and low uri-
nary CER (SHR = 0.32, 95% CI: 0.16–0.66, P= 0.002) were identified as
the strongest predictors of cardiovascular mortality. Other risk factors
for cardiovascular mortality were high age (SHR = 1.05, 95% CI: 1.01–
1.10, P = 0.028), low eGFR (SHR = 0.74, 95% CI: 0.57–0.97 per
10 ml/min per 1.73 m2, P= 0.029), low albumin (SHR = 0.88, 95% CI:
0.83–0.94, P b 0.001), high ALP (SHR = 1.02, 95% CI: 1.02–1.03 per
10 U/L, P b 0.001), high direct bilirubin (SHR = 1.02, 95% CI: 1.01–1.03,
P b 0.001), and transplant era (SHR=3.16, 95% CI: 1.05–9.54, P=0.041).
Furthermore, change in BMI in the first-year post-transplantation
compared to pre-transplantation, was analysed (Table 6). BMI pre-
transplantationwasmeasured at amedianof 35.0 (IQR8.5–80.0) days be-
fore transplantation. The vast majority of obese recipients 1-year post-
transplantationwere either overweight, or obese prior to transplantation.
Normal-weight OLT recipients prior to transplantation rarely progressed
to obesity after 1 year (Table 6). Change in BMIwas not significantly asso-
ciated with all-cause mortality (Supplementary Table S3). Results
remained non-significant after correction for pre-transplant ascites (Sup-
plementary Table S4). Analyses excluding OLT recipients with pre-
transplant ascites, showed similar results (Supplementary Table S5).
4. Discussion
This study demonstrates that high BMI at 1 year after OLT is associ-
ated with increased risk of long-term all-cause mortality in OLT recipi-
ents. Furthermore, obese OLT recipients have a 2-fold increased risk of
long-term all-cause mortality compared to normal weight OLT recipi-
ents. This underlines the importance of an adequate post-transplant
BMI on long-term survival after OLT.
OLT recipients have approximately 20% reduced survival rates when
compared to the general population [30]. In the current study, this sur-
vival rate was comparable for normal weight OLT recipients. Obese OLT
recipients, however, had an additional 20% decrease in survival rate.
Moreover, obese OLT recipients have a 2-fold higher risk of mortality
compared to normal weight OLT recipients, which is substantially
more than obese people in the general population when compared to
normal weight people (HR=1.18, 95% CI: 1.12–1.25) [31]. This empha-
sizes the importance of a healthy weight for OLT recipients.
In the general population, a high BMI is associatedwith the develop-
ment of cardiovascular diseases, diabetes, musculoskeletal disorders
and cancer, resulting in increased morbidity andmortality [16]. Obesity
is the hallmark ofmetabolic syndrome, ofwhichhypertension, hypertri-
glyceridemia, hyperglycaemia, and low serum high density lipoprotein
(HDL) cholesterol are other components [32]. Our study reveals that
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serum triglycerides, and higher glucose levels, when compared to OLT
recipients with normal weight at 1 year post-transplantation. Interest-
ingly, we found no significant association of BMI with cardiovascular
mortality. We hypothesize that cardiovascular mortality is at least
partly prevented because OLT recipients are periodically screened for
cardiovascular risk factors (e.g. blood-pressure, serum glucose and cho-
lesterol) on follow-up and adequately treated if necessary, when com-
pared to the general population [33].
In our study, BMIwas different across categories of primary liver dis-
ease, indicating that primary liver disease is associated with BMI 1-year
post-transplantation. However, as demonstrated in model 3, BMI
remained significantly associated with mortality despite adjustment
for primary liver disease, indicating that high post-transplant BMI is as-
sociatedwith long-termmortality, independent of primary liver disease.
In this study, a BMI ≥ 30 kg/m2 was associated with a significantly
higher mortality risk, but we did not stratify obese OLT recipients into
further categories of obesity. Nevertheless, Fig. 3 depicts an exponential
relation between BMI and all-cause mortality in OLT recipients. Thus,
further research is warranted to investigate potential differences in
mortality risk in OLT recipients with a BMI N 35 kg/m2 and BMI
N 40 kg/m2 post-transplantation.
In the literature, associations between overweight and obesity on
long-term survival after OLT are inconsistent [15]. Some studies re-
vealed that high BMI was associated with higher mortality rates
[30,34–39], whereas in other studies BMI was not identified as an inde-
pendent predictor of patient survival [21,22,40–46]. Importantly, these
studies have mainly focussed on pre-transplant BMI, while the effects
of post-transplant BMI (i.e., the subject of this study) have been investi-
gated only to a limited extent.
Previous studies demonstrated that time-dependent BMI or increase
in BMI post-transplantation is associated with better patient survival,
which is inconsistent with our study results [47,48]. This might be ex-
plained by differences in study design (e.g. change in BMI, time-
dependent BMI, or BMI 1 year post-transplantation was used), differ-
ences in multivariable analyses, or the exclusion of patients with a
BMI N 25 kg/m2 in one study [48].
No significant differences were found in urinary CER between BMI
groups. Therefore, in our study, weight gain after OLT was mostly due
to an increase in fat mass, whereas muscle mass was independent of
body weight. This increase in fat mass can be accelerated by poor life-
style factors, including dietary intake, reduced physical activity, and im-
munosuppressive medication [20,23,49]. Although there is evidence
that physical exercise improves long-term quality of life after OLT [50],
studies on nutritional and physical-activity based interventions on
long-term survival after OLT are currently lacking. Therefore, future
studies concerning the effects of dietary advice and physical exercise
on long-term survival are warranted. Furthermore, in selected patients,
bariatric surgery, in particular sleeve gastrectomy,might be feasible and
results in weight loss [51,52]. More research, however, is warranted to
minimize risk of complications after bariatric surgery in OLT recipients.
Optimal timing of bariatric surgery for obese recipients (i.e., before, dur-
ing, or after OLT), remains to be defined [51,52].
This study has some valuable strengths. This study is characterized
by an excellent follow-up. Median follow-up was 12,3 years (IQR 8.4–
15.0 years) and only 1 OLT recipient was lost to follow-up. Additionally,
only 13 OLT recipients (3%) were excluded because of missing baseline
data on BMI or urinary CER. Furthermore, potential confounders were
thoroughly addressed by using appropriate statistical analyses.
The current study has some limitations. The external validity of its
findings is limited, due to the single-center cohort design. Furthermore,
the post-hoc character of this study relies on adequate weight and
height measurements performed by health care professionals, although
we do not expect substantial variability among measurements.
In conclusion, post-transplant BMI is inversely associatedwith long-
term survival after OLT. Moreover, obesity at 1-year post-transplantation conveys a 2-fold higher mortality risk, which may
offer potential for interventional strategies (i.e. dietary advice, lifestyle
modification, or bariatric surgery) to improve long-term survival of
obese OLT recipients.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.metabol.2020.154204.
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